PUBLISHER: Orion Market Research | PRODUCT CODE: 1882953
PUBLISHER: Orion Market Research | PRODUCT CODE: 1882953
Global Ventricular Fibrillation Treatment Market Size, Share & Trends Analysis By Diagnostic Techniques (Electrocardiogram, Blood Test, Echocardiogram, Electrophysiology Study, and Others), By Treatment (Cardiopulmonary Resuscitation (CPR), Defibrillation, Pharmacological Therapy, Catheter Ablation, Cardiac Resynchronization Therapy (CRT), Left Cardiac Sympathetic Denervation, and Others), By Route Of Administration (Intravenous (IV), Intraosseous (IO), Oral, and Others), and By End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, and Others) Forecast Period (2026-2035)
Industry Overview
Ventricular fibrillation treatment market was valued at $15.4 billion in 2025 and is projected to reach $29 billion by 2035, growing at a CAGR of 6.0% from 2026 to 2035. Ventricular fibrillation is a life-threatening cardiac arrhythmia requiring immediate medical intervention. The increasing prevalence of cardiovascular diseases across the globe will create demand for the ventricular fibrillation treatment market. The changes in lifestyle, especially among youngsters, poor dietary habits, stress, smoking, and rising obesity rates, are increasing the risk of cardiac disorders. Thus, the number of sudden cardiac arrests is rising globally. For instance, the Sudden Cardiac Arrest Foundation highlighted the data from the American Heart Association Heart and Stroke Statistics.
Market Dynamics
Growing Investments by Market Players in R&D and Strategic Collaborations
The growth of the ventricular fibrillation treatment market is witnessing a surge due to increasing investment in research and development and strategic partnerships. The market players are continuously taking strategic initiatives aiming to accelerate innovation in cardiac rhythm management. Additionally, strategic collaborations among medical device manufacturers, research institutes, and healthcare providers are boosting market growth. For instance, in February 2024, Arga Medtech announced the closure of a €54M oversubscribed Series B funding. The round was led by the existing investors, Advent Life Sciences (UK) and Earlybird Health (Germany), as well as new investor Gilde Healthcare (the Netherlands) and an undisclosed strategic investor. The investment enabled the company to advance the development of its innovative CSE Pulsed Field Ablation (PFA). With the funding, the company further expanded its US offices in San Diego, CA.
Growing Demand for Safer, Faster, and More Precise Treatment Options
The growing demand for safer, faster, and more precise treatment options for ventricular arrhythmias is expected to create a demand for the market during the forecast period. Further, the growing incidence of ventricular fibrillation and tachycardia across the globe will further push toward pulsed field ablation (PFA). For instance, in May 2024, Field Medical announced the human trials for FieldForce Ventricular Pulsed Field Ablation Technology. The PFA technology is capable of achieving rapid, complete transmural left ventricular (LV) ablation. The technology further offers highly targeted treatment options and an efficient workflow.
Market Segmentation
Electrocardiogram Segment is Expected to Lead the Market with the Largest Share
An electrocardiogram (ECG) is expected to hold the largest market share during the forecast period. An electrocardiogram test is a non-invasive type of medical test that records the heart's activity. The test further identifies abnormal ventricular rhythms rapidly. ECG is considered the frontline diagnostic tool across hospitals to deliver real-time insights for immediate intervention. The integrations of AI along with portable ECG systems further increase diagnostic accuracy. For instance, in December 2024, HeartBeam announced that the company had received FDA Clearance of the HeartBeam system for comprehensive arrhythmia assessment. This system comes with a credit card-sized form factor and cable-free design, and it captures heart signals from three distinct directions for actionable heart health information.
Global Ventricular Fibrillation Treatment Market Share by Diagnostic Techniques, 2024 (%)
Source: OMR Analysis
Defibrillation: A Key Segment in Market Growth
Defibrillation is expected to be a key segment in the market growth during the forecast period. Defibrillation is capable of restoring a normal cardiac rhythm during ventricular fibrillation. The growing awareness of sudden cardiac arrest (SCA) management is rising demand for advanced defibrillators, ranging from automated external defibrillators (AEDs) to implantable cardioverter-defibrillators (ICDs). The demand for advanced defibrillators is also growing as they improve survival rates with early shock delivery. For instance, Medtronic received FDA approval for an extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest.
The global ventricular fibrillation treatment market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region Dominates the Market with a Major Share
The North American region is expected to dominate the market share during the forecast period. The factors such as the presence of strong and high adoption of defibrillators and cardiac devices, advanced healthcare infrastructure, and strong presence of key market players will propel the North American ventricular fibrillation treatment market during the forecast period. The high awareness of cardiac arrest management in countries such as the US and Canada will further drive the market growth. For instance, in December 2024, Oregon Health & Science University coordinated with other emergency service providers to launch a three-year clinical trial. The clinical trial is to test giving patients in cardiac arrest earlier treatment with a drug, amiodarone. The treatment will further aid in restoring & maintaining normal heart rhythms.
Europe Region to Grow at a Substantial Rate
Among all regions, Europe is expected to provide a substantial growth rate to the market due to the rising incidence of cardiovascular diseases. The continuous technological advancements, well-established healthcare infrastructure, along with supportive regulatory policies will further drive the market growth. For instance, in February 2024, Biosense Webster company announced that the company got regulatory approval for VARIPULSE Pulsed Field Ablation (PFA) Platform in Europe. The VARIPULSE(TM) Platform is the first and only CARTO-integrated PFA system, enabling an intuitive and reproducible workflow with real-time visualization and feedback mechanisms.
The major companies operating in the global ventricular fibrillation treatment market include Abbott Laboratories, Advanced Instrumentations Inc., Amgen Inc., AstraZeneca PLC, Baxter International Inc., Bexen Cardio, Biotronik SE & Co. KG, Boston Scientific Corp., and CU Medical Systems, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development